Positioning
THEDERMALFILLER® presents a curated portfolio of CE-marked injectable hyaluronic acid medical devices placed on the EU market in accordance with Regulation (EU) 2017/745 (MDR). Access is restricted to licensed healthcare professionals operating within authorised clinical environments.
Professional Access Conditions
– Professional verification required
– No public price listing
– No anonymous procurement
– Portfolio displayed for professional reference only
– Traceability ensured via authorised EU economic operators
– Structural volumisation and deep tissue support
– Midface contouring and projection
– Jawline and chin definition
– Lip structure and border refinement
– Periorbital correction
– Superficial fine line treatment
– Nasolabial and marionette fold correction
– High G’ structural fillers
– Balanced contour formulations
– Soft integration superficial fillers
– Low-density skin quality injectables
Dermal fillers within this portfolio vary based on:
– Cross-linking technology
– Rheological profile (G’, cohesivity, elasticity)
– Projection capacity
– Tissue integration behaviour
– Depth of placement
Product selection remains the sole clinical responsibility of the licensed practitioner.
CE-marked medical devices under Regulation (EU) 2017/745 (MDR), manufactured by Merz Aesthetics. Cross-linked hyaluronic acid portfolio based on Cohesive Polydensified Matrix (CPM®) technology, developed for aesthetic soft-tissue augmentation and correction of facial volume deficits. Intended exclusively for use by licensed healthcare professionals within authorised clinical settings.
Indication
Treatment of superficial to moderate facial lines and fine wrinkles.
Hyaluronic Acid Concentration
20.0 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Technology
Cohesive Polydensified Matrix (CPM®).
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of deep facial wrinkles and enhancement of lip volume.
Hyaluronic Acid Concentration
25.5 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Technology
CPM® technology.
Regulatory Status
CE-marked medical device.
Indication
Correction of moderate to severe facial folds, including nasolabial folds.
Hyaluronic Acid Concentration
22.5 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device.
Indication
Restoration of facial volume in deeper dermal and subdermal layers.
Hyaluronic Acid Concentration
26.0 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device.
Indication
Lip contouring and volumisation.
Hyaluronic Acid Concentration
25.5 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 0.6 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device.
Indication
Definition of lip contour and correction of perioral lines.
Hyaluronic Acid Concentration
22.5 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 0.6 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device.
Indication
Skin revitalisation and improvement of skin elasticity and hydration.
Hyaluronic Acid Concentration
20.0 mg/mL hyaluronic acid with glycerol component.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device.
CE-marked injectable implant in accordance with Regulation (EU) 2017/745 (MDR), manufactured by Merz Aesthetics. Calcium hydroxylapatite (CaHA) microspheres suspended in a sterile aqueous gel carrier, developed for soft-tissue augmentation and facial contour restoration within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Soft-tissue augmentation and correction of facial volume loss in deeper dermal and subdermal layers.
Composition
30% calcium hydroxylapatite (CaHA) microspheres
70% aqueous gel carrier.
Presentation
1 × 1.5 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Soft-tissue augmentation and facial contour correction with integrated local anaesthetic component.
Composition
Calcium hydroxylapatite (CaHA) microspheres
Aqueous gel carrier
0.3% lidocaine hydrochloride.
Presentation
1 × 1.5 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked hyaluronic acid dermal filler portfolio manufactured by Galderma in accordance with Regulation (EU) 2017/745 (MDR). The range incorporates NASHA® and OBT® technologies, developed for controlled tissue integration, volumetric support and facial contour correction within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Deep dermal and subdermal implantation for facial volume restoration and contour enhancement.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
NASHA® technology.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of deep nasolabial folds and marionette lines.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
XpresHAn Technology™ (OBT®).
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate facial wrinkles and folds.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
XpresHAn Technology™ (OBT®).
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Facial volume restoration in deeper dermal layers.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
XpresHAn Technology™ (OBT®).
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip augmentation and enhancement of lip contour.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
XpresHAn Technology™ (OBT®).
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Cheek augmentation and mid-face contour restoration.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
XpresHAn Technology™ (OBT®).
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Skin revitalisation and improvement of hydration and elasticity.
Hyaluronic Acid Concentration
20 mg/mL stabilised hyaluronic acid.
Technology
NASHA® technology.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Hydration treatment for thinner or delicate skin areas.
Hyaluronic Acid Concentration
12 mg/mL stabilised hyaluronic acid.
Technology
NASHA® technology.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of infraorbital hollowing (tear trough).
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
NASHA® technology.
Presentation
1 × 0.5 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked hyaluronic acid dermal filler portfolio manufactured by Teoxane Laboratories in accordance with Regulation (EU) 2017/745 (MDR). The range integrates RHA® (Resilient Hyaluronic Acid) and cross-linked hyaluronic acid technologies, developed for adaptive tissue integration, facial volumisation and dynamic wrinkle correction within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Correction of superficial to moderate facial wrinkles.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of deep wrinkles and nasolabial folds.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Restoration of facial volume in deeper dermal layers.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip augmentation and contour definition.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of infraorbital hollowing (tear trough area).
Hyaluronic Acid Concentration
15 mg/mL cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of superficial dynamic wrinkles.
Hyaluronic Acid Concentration
15 mg/mL resilient cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Technology
RHA® (Resilient Hyaluronic Acid).
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate dynamic wrinkles.
Hyaluronic Acid Concentration
23 mg/mL resilient cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Technology
RHA® technology.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of deeper dynamic wrinkles and facial folds.
Hyaluronic Acid Concentration
23 mg/mL resilient cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Technology
RHA® technology.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Volume restoration and structural contouring in deeper dermal layers.
Hyaluronic Acid Concentration
23 mg/mL resilient cross-linked hyaluronic acid.
Presentation
2 × 1 mL prefilled sterile syringes.
Technology
RHA® technology.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip augmentation and perioral contour enhancement.
Hyaluronic Acid Concentration
23 mg/mL resilient cross-linked hyaluronic acid.
Presentation
2 × 0.7 mL prefilled sterile syringes.
Technology
RHA® technology.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked hyaluronic acid dermal filler portfolio manufactured by Allergan Aesthetics (AbbVie) in accordance with Regulation (EU) 2017/745 (MDR). The range incorporates cross-linked hyaluronic acid formulations including Vycross® and Hylacross® technologies, developed for facial volumisation, contour restoration and wrinkle correction within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Correction of superficial facial wrinkles and fine lines.
Hyaluronic Acid Concentration
24 mg/mL cross-linked hyaluronic acid.
Technology
Hylacross® technology.
Presentation
2 × 0.55 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate facial wrinkles and lip augmentation.
Hyaluronic Acid Concentration
24 mg/mL cross-linked hyaluronic acid.
Technology
Hylacross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of deep facial wrinkles and facial contour restoration.
Hyaluronic Acid Concentration
24 mg/mL cross-linked hyaluronic acid.
Technology
Hylacross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip contouring and volumisation.
Hyaluronic Acid Concentration
24 mg/mL cross-linked hyaluronic acid.
Technology
Hylacross® technology.
Presentation
2 × 0.55 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip augmentation and correction of perioral lines.
Hyaluronic Acid Concentration
15 mg/mL cross-linked hyaluronic acid.
Technology
Vycross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate to severe facial folds and contour deficiencies.
Hyaluronic Acid Concentration
17.5 mg/mL cross-linked hyaluronic acid.
Technology
Vycross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Restoration of facial volume in deeper dermal and subdermal layers.
Hyaluronic Acid Concentration
20 mg/mL cross-linked hyaluronic acid.
Technology
Vycross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Structural facial contouring and jawline definition.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Technology
Vycross® technology.
Presentation
2 × 1 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked hyaluronic acid dermal filler portfolio manufactured by Croma-Pharma GmbH in accordance with Regulation (EU) 2017/745 (MDR). The range consists of cross-linked hyaluronic acid formulations developed for facial contour refinement, volume restoration and wrinkle correction within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Improvement of skin hydration and dermal revitalisation.
Hyaluronic Acid Concentration
18 mg/mL hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate facial wrinkles and contour refinement.
Hyaluronic Acid Concentration
23 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of moderate facial wrinkles and contour refinement.
Hyaluronic Acid Concentration
23 mg/mL cross-linked hyaluronic acid with lidocaine.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Restoration of facial volume in deeper dermal layers.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Structural contouring and enhanced facial volume restoration.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked injectable hyaluronic acid medical device manufactured by IBSA Farmaceutici Italia S.r.l., in accordance with Regulation (EU) 2017/745 (MDR). The product consists of stabilized hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid, developed for dermal bio-remodelling within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Dermal bio-remodelling and improvement of skin laxity.
Hyaluronic Acid Concentration
64 mg/2 mL (32 mg high molecular weight + 32 mg low molecular weight hyaluronic acid).
Presentation
1 × 2 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Restoration of adipose tissue support and structural dermal bio-remodelling.
Hyaluronic Acid Concentration
90 mg/2 mL hybrid cooperative complex hyaluronic acid.
Presentation
1 × 2 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked injectable medical device manufactured by Galderma in accordance with Regulation (EU) 2017/745 (MDR). Sculptra® is an injectable poly-L-lactic acid (PLLA) biostimulatory device intended for subdermal implantation to support gradual collagen stimulation and progressive volume restoration within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Correction of facial volume loss and contour deficiencies through collagen stimulation.
Composition
Poly-L-lactic acid 150 mg per vial.
Presentation
1 sterile vial containing lyophilised powder for reconstitution prior to injection.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked injectable medical device manufactured by Allergan Aesthetics (AbbVie) in accordance with Regulation (EU) 2017/745 (MDR). HarmonyCa® is a hybrid injectable combining calcium hydroxyapatite (CaHA) microspheres and cross-linked hyaluronic acid, intended to provide immediate volume restoration together with progressive collagen stimulation within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Facial contour restoration and structural support with combined volumising and biostimulatory effect.
Composition
Calcium hydroxyapatite (CaHA) microspheres combined with cross-linked hyaluronic acid.
Presentation
2 × 1.25 mL prefilled sterile syringes.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
CE-marked hyaluronic acid dermal filler portfolio manufactured by IBSA Farmaceutici Italia S.r.l., in accordance with Regulation (EU) 2017/745 (MDR). Aliaxin® consists of high-purity cross-linked hyaluronic acid formulations developed for facial contouring, volumisation and hydration within regulated medical aesthetic practice. Intended exclusively for use by licensed healthcare professionals.
Indication
Correction of moderate facial wrinkles and contour refinement.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Lip augmentation and perioral contour definition.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Skin revitalisation and dermal hydration improvement.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Restoration of facial volume and structural support.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Correction of fine lines and superficial facial wrinkles.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
Indication
Facial volume restoration and contour enhancement.
Hyaluronic Acid Concentration
25 mg/mL cross-linked hyaluronic acid.
Presentation
1 × 1.0 mL prefilled sterile syringe.
Regulatory Status
CE-marked medical device under MDR (EU) 2017/745.
Intended User
Licensed healthcare professionals.
THEDERMALFILLER® operates exclusively as an independent EU commercial intermediary facilitating professional procurement between licensed healthcare providers and authorised EU manufacturers or pharmaceutical wholesalers. All product listings and any pricing references are provided strictly for internal professional orientation and do not constitute a public offer, retail offer, binding quotation or invitation to purchase. Access to commercial information, quotations and supply is restricted exclusively to verified healthcare professionals and authorised medical entities.
Regulatory Status and Operational Model
This platform is not a retailer, distributor or marketplace. No public offer is made. All commercial flows occur exclusively through authorised EU economic operators.
No consumer access. No retail rights.
THEDERMALFILLER® operates exclusively as an independent European Union B2B commercial intermediary within a regulated professional framework.
No manufacturing
No importing
No stock holding
No distribution
No retail activity
All products are supplied and delivered by authorised EU manufacturers or licensed pharmaceutical wholesalers.
TheDermalFiller acts exclusively as an independent EU commercial intermediary.
Access restricted to licensed healthcare professionals.
No contractual relationship is formed via this website.
© 2026 THEDERMALFILLER®
This website is intended exclusively for licensed medical professionals within the European Union.
By continuing, you confirm that you are a certified healthcare or aesthetic professional and that you access this platform for professional purposes only.